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Abstract 13 
Sequencing-based studies have identified novel risk genes for rare, severe epilepsies and 14 
revealed a role of rare deleterious variation in common epilepsies. To identify the shared and 15 
distinct ultra-rare genetic risk factors for rare and common epilepsies, we performed a whole-16 
exome sequencing (WES) analysis of 9,170 epilepsy-affected individuals and 8,364 controls of 17 
European ancestry. We focused on three phenotypic groups; the rare but severe developmental 18 
and epileptic encephalopathies (DEE), and the commoner phenotypes of genetic generalized 19 
epilepsy (GGE) and non-acquired focal epilepsy (NAFE). We observed that compared to controls, 20 
individuals with any type of epilepsy carried an excess of ultra-rare, deleterious variants in 21 
constrained genes and in genes previously associated with epilepsy, with the strongest 22 
enrichment seen in DEE and the least in NAFE. Moreover, we found that inhibitory GABAA 23 
receptor genes were enriched for missense variants across all three classes of epilepsy, while no 24 
enrichment was seen in excitatory receptor genes. The larger gene groups for the GABAergic 25 
pathway or cation channels also showed a significant mutational burden in DEE and GGE. 26 
Although no single gene surpassed exome-wide significance among individuals with GGE or 27 
NAFE, highly constrained genes and genes encoding ion channels were among the top 28 
associations, including CACNA1G, EEF1A2, and GABRG2 for GGE and LGI1, TRIM3, and 29 
GABRG2 for NAFE. Our study confirms a convergence in the genetics of common and rare 30 
epilepsies associated with ultra-rare coding variation and highlights a ubiquitous role for 31 
GABAergic inhibition in epilepsy etiology in the largest epilepsy WES study to date.  32 
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Introduction 33 
Epilepsy is a group of disorders characterized by repeated seizures due to excessive electrical 34 
activity in the brain, one of the most common and burdensome neurological conditions worldwide1; 35 
2. A core challenge for epilepsy genetics is identifying and disentangling the genetic architecture 36 
and biological mechanisms underlying the variety of epilepsy types (e.g., focal vs. generalized) 37 
and electroclinical syndromes. While the occurrence of epilepsy for many affected individuals 38 
carries an underlying genetic component3-5, the highly heterogeneous nature of epileptic seizures, 39 
epilepsy types, severity, and comorbidity makes it difficult to determine the specific genetic risks 40 
for each patient. For individuals with common, complex types of epilepsy, where inheritance may 41 
be due to strongly acting mutations, oligogenic or polygenic, the discovery of genetic risk factors 42 
is particularly challenging. 43 
 Considerable progress in our understanding of the genetic risk factors for epilepsy has 44 
been made in recent years thanks to the rapid growth and advancement in sequencing technology. 45 
Dozens of epilepsy-causing genes have been identified in individuals diagnosed with severe 46 
epilepsy syndromes6-10, known as the developmental and epileptic encephalopathies (DEE). DEE 47 
are rare in the population and typically begin early in life. Incidence of the entire group is not well 48 
established, but a recent epidemiological study of severe epilepsies limited to onset under 18 49 
months found an incidence of 1 in 2000 births11. The incidence of Dravet syndrome, one of the 50 
important specific forms of DEE, has been shown in several studies as 1 in 22,00010. Individuals 51 
with DEE usually have developmental impairment, ranging from profound to mild. With such 52 
severity, sequencing-based studies continue to discover de novo pathogenic variants for DEE 53 
and have implicated genes encoding neuronal ion channels and receptors and genes involved in 54 
cellular signaling6-10; 12. The common subgroups of epilepsy, broadly comprising genetic 55 
generalized epilepsy (GGE) and non-acquired focal epilepsy (NAFE), account for a major 56 
proportion of all incident epilepsies2; 13 and have been shown robust heritability in twin, family, and 57 
genome-wide association studies (GWAS)4; 14-16. Disappointingly, only a limited number of genes 58 
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had been discovered to date for the common epilepsies, mostly from rare monogenic families with 59 
focal epilepsies, and attempts to identify clear risk genes for GGE have been least successful12; 60 
17; 18. In most cases, especially for non-familial onset, the specific pathogenic variants are not yet 61 
known, and gene findings from small-scale studies have often not been reproducible19-21. 62 
 Current evidence of the genetic etiology of epilepsies has revealed both extensive 63 
phenotypic and genetic heterogeneity. Many of the identified genes are associated with a 64 
spectrum of mild to severe epilepsies, showing phenotypic pleiotropy or variable expressivity, and 65 
most of the electroclinical syndromes have diverse genetic causes10; 22. Two recent studies using 66 
whole-exome sequencing (WES) of hundreds of individuals with common familial epilepsies found 67 
an enrichment in ultra-rare genetic variation in genes associated with rare epilepsy syndromes17 68 
and in missense variants in a group of genes encoding all GABAA receptors, the most important 69 
neurotransmitter receptors for neuronal inhibition in the mammalian brain18. Given the complex 70 
genetic architecture of the epilepsies, it is therefore critical to pinpoint the distinct and overlapping 71 
genetic risk factors underlying different groups of epilepsy on a scale much larger than previous 72 
sequencing studies and beyond familial cases. 73 
Here, we evaluate a WES case-control study of epilepsy from the Epi25 collaborative—74 
an ongoing global effort that collected an unprecedented number of patient cohorts for primarily 75 
the three major classes of non-lesional epilepsies: DEE, GGE, and NAFE22. We aimed to 76 
characterize the genetic risk of ultra-rare coding variants across these common and rare epilepsy 77 
subgroups by evaluating the burden at the individual gene level and in candidate gene sets to 78 
understand the role of rare genetic variation in epilepsy and identify specific epilepsy risk genes.  79 
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Subjects and Methods 80 
Study design and participants 81 
We collected DNA and detailed phenotyping data on individuals with epilepsy from 37 sites in 82 
Europe, North America, Australasia and Asia (Supplemental Subjects and Methods; Table S1).  83 
Here we analyzed subjects with genetic generalized epilepsy (GGE, also known as idiopathic 84 
generalized epilepsy; N=4,453), non-acquired focal epilepsy (NAFE; N=5,331) and 85 
developmental and epileptic encephalopathies (DEE; N=1,476); and a small number of other 86 
epilepsies were also included in the initiative (Table S1).   87 
Control samples were aggregated from local collections at the Broad Institute (Cambridge, 88 
MA, USA) or obtained from dbGaP, consisting of 17,669 individuals of primarily European 89 
ancestry who were not ascertained for neurological or neuropsychiatric conditions (Table S2; 90 
Supplemental Subjects and Methods). 91 
Phenotyping procedures   92 
Epilepsies were diagnosed on clinical grounds based on criteria given in the next paragraph (see 93 
below for GGE, NAFE and DEE, respectively) by experienced epileptologists and consistent with 94 
International League Against Epilepsy (ILAE) classification at the time of diagnosis and 95 
recruitment. De-identified (non-PHI [protected health information]) phenotyping data were entered 96 
into the Epi25 Data repository hosted at the Luxembourg Centre for Systems Biomedicine via 97 
detailed on-line case record forms based on the RedCAP platform. Where subjects were part of 98 
previous coordinated efforts with phenotyping on databases (e.g., the Epilepsy 99 
Phenome/Genome Project23 and the EpiPGX project (www.epipgx.eu)), deidentified data were 100 
accessed and transferred to the new platform. Phenotyping data underwent review for uniformity 101 
among sites and quality control by automated data checking, followed by manual review if 102 
required. Where doubt remained about eligibility, cases were reviewed by the phenotyping 103 
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committee and sometimes further data was requested from the source site before a decision was 104 
made. 105 
Case Definitions 106 
GGE required a convincing history of generalized seizure types (generalized tonic-clonic seizures, 107 
absence, or myoclonus) and generalized epileptiform discharges on EEG. We excluded cases 108 
with evidence of focal seizures, or with moderate to severe intellectual disability and those with 109 
an epileptogenic lesion on neuroimaging (although neuroimaging was not obligatory). If a 110 
diagnostic source EEG was not available, then only cases with an archetypal clinical history as 111 
judged by the phenotyping committee (e.g., morning myoclonus and generalized tonic-clonic 112 
seizures for a diagnosis of Juvenile Myoclonic Epilepsy) were accepted. 113 
Diagnosis of NAFE required a convincing history of focal seizures, an EEG with focal 114 
epileptiform or normal findings (since routine EEGs are often normal in focal epilepsy), and 115 
neuroimaging showing no epileptogenic lesion except hippocampal sclerosis (MRI was preferred 116 
but CT was accepted). Exclusion criteria were a history of generalized onset seizures or moderate 117 
to severe intellectual disability. 118 
The DEE group comprised subjects with severe refractory epilepsy of unknown etiology 119 
with developmental plateau or regression, no epileptogenic lesion on MRI, and with epileptiform 120 
features on EEG. As this is the group with the largest number of gene discoveries to date, we 121 
encouraged inclusion of those with non-explanatory epilepsy gene panel results, but we did not 122 
exclude those without prior testing (Table S7). 123 
Informed Consent 124 
Patients or their legal guardians provided signed informed consent according to local national 125 
ethical requirements.  Samples had been collected over a 20-year period in some centers, so the 126 
consent forms reflected standards at the time of collection. Samples were only accepted if the 127 
consent did not exclude data sharing. For samples collected after January 25, 2015, consent 128 
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forms required specific language according to the NIH Genomic Data Sharing policy 129 
(http://gds.nih.gov/03policy2.html). 130 
 131 
Whole exome sequencing data generation 132 
All samples were sequenced at the Broad Institute of Harvard and MIT on the Illumina HiSeq X 133 
platform, with the use of 151 bp paired-end reads. Exome capture was performed with Illumina 134 
Nextera® Rapid Capture Exomes or TruSeq Rapid Exome enrichment kit (target size 38 Mb), 135 
except for three control cohorts (MIGen ATVB, MIGen Ottawa, and Swedish SCZ controls) for 136 
which the Agilent SureSelect Human All Exon Kit was used (target size 28.6 Mb – 33 Mb). 137 
Sequence data in the form of BAM files were generated using the Picard data-processing pipeline 138 
and contained well-calibrated reads aligned to the GRCh37 human genome reference. Samples 139 
across projects were then jointly called via the Genome Analysis Toolkit (GATK) best practice 140 
pipeline24 for data harmonization and variant discovery. This pipeline detected single nucleotide 141 
(SNV) and small insertion/deletion (indel) variants from exome sequence data. 142 
 143 
Quality control  144 
Variants were pre-filtered to keep only those passing the GATK VQSR (Variant Quality Score 145 
Recalibration) metric and those lying outside of low complexity regions25. Genotypes with GQ < 146 
20 and heterozygous genotype calls with allele balance > 0.8 or < 0.2 were set to missing. To 147 
control for capture platform difference, we retained variants that resided in GENCODE coding 148 
regions where 80% of Agilent and Illumina-sequenced samples show at least 10x coverage. This 149 
resulted in the removal of ~50% of the called sites (23% of the total coding variants and 97% of 150 
the total non-coding variants) but effectively reduced the call rate difference between cases and 151 
controls (Figure S1). To further identify potential false positive sites due to technical variation, we 152 
performed single variant association tests (for variants with a minor allele frequency MAF > 0.001) 153 
among the controls, treating one platform as the pseudo-case group with adjustment for sex and 154 
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the first ten principal components (PCs), and removed variants significantly associated with 155 
capture labels (p-value < 0.05). We also excluded variants with a call rate < 0.98, case-control 156 
call rate difference > 0.005, or Hardy-Weinberg Equilibrium (HWE) test p-value < 1×10-6 based 157 
on the combined case and control cohort. 158 
Samples were excluded if they had a low average call rate (< 0.98), low mean sequence 159 
depth (< 30; Figure S2), low mean genotype quality (< 85), high freemix contamination estimate 160 
(> 0.04), or high percent chimeric reads (> 1.4%). We performed a series of principal component 161 
analyses (PCAs) to identify ancestral backgrounds and control for population stratification, 162 
keeping only individuals of European (EUR) ancestry classified by Random Forest with 1000 163 
Genomes data (Figure S3). Within the EUR population, we removed controls not well-matched 164 
with cases based on the top two PCs, and individuals with an excessive or a low count of 165 
synonymous singletons—a number that increases with the North-to-South axis (Figure S4). We 166 
also removed one sample from each pair of related individuals (proportion identity-by-descent > 167 
0.2) and those whose genetically imputed sex was ambiguous or did not match with self-reported 168 
sex. Outliers (>4SD from the mean) of transition/transversion ratio, heterozygous/homozygous 169 
ratio, or insertion/deletion ratio within each cohort were further discarded (Figures S5-7). At the 170 
phenotype level, we removed individuals with epilepsy phenotype to-be-determined or marked as 171 
“excluded” from further review.    172 
The number of variant and sample dropouts at each step are detailed in Tables S3 and 173 
S4.  174 
 175 
Variant annotation 176 
Annotation of variants was performed with Ensembl’s Variant Effect Predictor (VEP)26 for human 177 
genome assemble GRCh37. Based on the most severe consequence, we defined four mutually 178 
exclusive functional classes of variants using relevant terms and SnpEff27 impact (Table S5): 179 
protein-truncating variant (PTV), damaging missense (predicted by PolyPhen-2 and SIFT), 180 
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other/benign missense (predicted by PolyPhen-2 and SIFT), and synonymous. To further 181 
discriminate likely deleterious missense variants from benign missense variants, we applied an in 182 
silico missense deleteriousness predictor (“Missense badness, PolyPhen-2, and regional 183 
Constraint”, or MPC score)28 that leverages regional constraint information to annotate a subset 184 
of missense variants that are highly deleterious (MPC ≥ 2). The MPC ≥ 2 group accounts for a 185 
small proportion of the total damaging and benign missense variants annotated by PolyPhen-2 186 
and SIFT. Because many of our control samples were obtained from external datasets used in 187 
the Exome Aggregation Consortium (ExAC)29 (Table S2), we used the DiscovEHR cohort—an 188 
external population allele frequency reference cohort that contains 50,726 whole-exome 189 
sequences from a largely European and non-diseased adult population30—to annotate if a variant 190 
is absent in the general population (Figure S8). 191 
 192 
Gene-set burden analysis 193 
To estimate the excess of rare, deleterious protein-coding variants in individuals with epilepsy, 194 
we conducted burden tests across the entire exome, for biologically relevant gene sets and at the 195 
individual gene level. We focused on two definitions of “ultra-rare” genetic variation (URV) for the 196 
primary analyses—variants not seen in the DiscovEHR database and observed only once among 197 
the combined case and control test cohort (allele count AC=1) or absent in DiscovEHR and 198 
observed no more than three times in the test cohort (allele count AC≤3)—where the strongest 199 
burden of deleterious pathogenic variants have been observed previously17; 31 and in our study 200 
compared to less stringent allele frequency thresholds (Figure S9 & S10). We performed these 201 
case-control comparisons separately for each of the three primary epilepsy disorders (DEE, GGE, 202 
NAFE) and again for all epilepsy-affected individuals combined. 203 
 Gene-set burden tests were implemented using logistic regression to examine the 204 
enrichment of URVs in individuals with epilepsy versus controls. We performed the test by 205 
regressing case-control status on certain classes of URVs aggregated across a target gene set 206 
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in an individual, adjusting for sex, the top ten PCs, and exome-wide variant count. This analysis 207 
tested the burden of URVs separately for five functional coding annotations: synonymous, benign 208 
missense predicted by PolyPhen-2 and SIFT, damaging missense predicted by PolyPhen-2 and 209 
SIFT, protein-truncating variants, and missense with MPC≥2 (Table S5). To help determine 210 
whether our burden model was well calibrated, we used synonymous substitutions as a negative 211 
control, where significant burden effects would more likely indicate insufficient control of 212 
population stratification or exome capture differences. The inclusion of overall variant count as a 213 
covariate—which tracks with ancestry—made our test conservative but allows for better control 214 
of residual population stratification not captured by PCs, and effectively reduces inflation of 215 
signals in synonymous variants (Figure S11). We collected and tested eleven different gene sets, 216 
including constrained genes, brain-enriched genes, and genes reported to be associated with 217 
epilepsy or epilepsy-related mechanisms9; 17; 18; 32; 33 (Table S6). Unlike the gene-based burden 218 
tests, because most of the gene-set tests were not independent, we used a false discovery rate 219 
(FDR) correction for multiple testing that accounted for the number of functional categories (5), 220 
gene sets (11) and epilepsy phenotypes (4), totaling 220 tests, and defined a significant 221 
enrichment at FDR < 0.05.  222 
 223 
Gene-based collapsing analysis 224 
 For gene-based tests, we restricted to deleterious URVs annotated as either PTV, 225 
missense with MPC≥2, or in-frame insertion/deletion. For each gene, individuals who had at least 226 
one copy of these deleterious variants were counted as a carrier, and we used a two-tailed 227 
Fisher’s Exact test (FET) to assess if the proportion of carriers among epilepsy subgroup cases 228 
was significantly higher than controls. Instead of assuming a uniform distribution for p-values 229 
under the null, we generated empirical p-values by permuting case-control labels 500 times, 230 
ordering the FET p-values of all genes for each permutation, and taking the average across all 231 
permutations to form a rank-ordered estimate of the expected p-value distribution. This was done 232 
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by modifying functions in the “QQperm” R package34. To avoid potential false discoveries, we 233 
defined a stringent exome-wide significance as p-value < 6.8e-07, using Bonferroni correction to 234 
account for 18,509 consensus coding sequence genes tested and the four individual case-control 235 
comparisons.  236 
Considering that recessive pathogenic variants were implicated in a number of epilepsy-237 
associated genes, mostly identified from individuals with a DEE phenotype7, we conducted a 238 
secondary gene-based Fisher’s exact test using a recessive model, comparing the proportion of 239 
carriers that are homozygous for the minor allele between cases and controls. The recessive 240 
model was assessed for PTVs, missense (MPC≥2) variants, and in-frame indels separately. For 241 
this analysis, we did not restrict to non-DiscovEHR variants and relaxed the allele frequency up 242 
to MAF < 0.01 to account for the sparse occurrences. 243 
Additionally, to evaluate the contribution of low frequency deleterious variants to epilepsy 244 
risk, we explored the gene burden of all protein-truncating and damaging missense variants for 245 
those with a MAF < 0.01 using SKAT35, including sex and the top ten PCs as covariates in the 246 
analysis. We performed the tests with the default weighting scheme (dbeta(1,25)). 247 
 248 
Single variant association 249 
Associations of common and low-frequency variants (MAF > 0.001) with epilepsy were estimated 250 
using logistic regression by Firth’s method, correcting for sex and the first ten PCs. 251 
 252 
Quality control, annotation, and analysis were largely performed using Hail36, an open-source 253 
software for scalable genomic data analysis, in conjunction with R (version 3.4.2).  254 
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Results 255 
Whole exome sequencing, quality control, and sample overview 256 
We performed WES on an initial dataset of over 30,000 epilepsy affected and control individuals. 257 
After stringent quality control (QC), we identified a total of 9,170 individuals with epilepsy and 258 
8,436 controls without reported neurological or neuropsychiatric-related conditions, all of whom 259 
were unrelated individuals of European descent. Among the individuals with epilepsy, 1,021 were 260 
diagnosed with DEE, 3,108 with GGE, 3,597 with NAFE, and 1,444 with other epilepsy syndromes 261 
(lesional focal epilepsy, febrile seizures, and others). Cases and controls were carefully matched 262 
on genetic ancestry to eliminate the possibility of false positive findings induced by population 263 
stratification. Due to the lack of cosmopolitan controls from non-European populations, cases 264 
identified from PCA with a non-European ancestry were removed. Furthermore, to ensure the 265 
distribution of rare variants was balanced between cases and controls37, we removed a subset of 266 
case and control-only cohorts (from Sweden, Finland, Cyprus, and Turkey) where the mean 267 
synonymous singleton count that significantly deviated from the overall average being the 268 
consequence of incomplete ancestry matching (Figure S4). We called a total of 1,844,644 sites 269 
in 18,509 genes in the final dataset, comprising 1,811,325 SNVs and 33,319 indels, 48.5% of 270 
which were absent in the DiscovEHR database30. Among the non-DiscovEHR sites, 85% were 271 
singletons (defined as only one instance of that variant), and 99% had a minor allele count (AC) 272 
not more than three (equivalent to MAF ≤0.01%; Figure S8); the missense with MPC≥2 273 
annotation accounted for 2.0% of the total missense variants (5.5% of the damaging and 1.0% of 274 
the benign missense variants predicted by PolyPhen-2 and SIFT). In our primary burden analyses, 275 
we focused on the “ultra-rare” non-DiscovEHR variants (URVs) that are unique to the 17,606 276 
individuals under study and are seen either only once (AC=1) or no more than three times (AC≤3) 277 
in our dataset. These URVs were shown to confer the largest risk of epilepsy compared to 278 
singletons observed in DiscovEHR, doubletons, or beyond (Figure S9 & S10). As previously 279 
described, epilepsy enrichment signals diminished with an increase in allele frequency17. 280 
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 281 
Enrichment of ultra-rare deleterious variants in constrained genes in DEE and GGE 282 
We first tested the burden of singleton URVs for each epilepsy subgroup, as well as for all 283 
epilepsy-affected individuals combined, versus controls among gene sets collected based on 284 
current understanding and hypothesis of epilepsy causation (Table S6). To evaluate the burden 285 
in constrained genes, we defined “loss-of-function (LoF) intolerant” genes with either a pLI score29 286 
> 0.9 (3,488 genes) or separately a pLI score > 0.995 (1,583 genes) and those as “missense-287 
constrained” for genes with a missense Z-score > 3.09 (1,730 genes)33. We used a version of the 288 
scores derived from the non-neuropsychiatric subset of the Exome Aggregation Consortium 289 
(ExAC) samples. Because some of our control cohorts are also in ExAC (Table S2), we restricted 290 
our constrained gene burden tests to controls outside of the ExAC cohort (N=4,042).  291 
We found that, consistent with a recent study that evaluated de novo burden in autism38, 292 
burden signals of PTVs were mostly contained in genes with a pLI > 0.995 compared to pLI > 0.9 293 
(Figure S12 & S13). Focusing on pLI > 0.995 in the all-epilepsy case-control analysis, both 294 
protein-truncating and damaging missense (MPC28≥2) URVs in LoF-intolerant genes showed a 295 
mutational burden with an odds ratio of 1.3 (adjP = 1.6×10-4) and 1.1 (adjP = 0.039), respectively. 296 
Breaking this down by epilepsy types, there was a significant excess of these deleterious URVs 297 
among individuals with DEE (ORPTV = 1.4, adjPPTV = 0.013; ORMPC = 1.2, adjPMPC = 0.019), as 298 
expected. This enrichment was also seen in individuals with GGE with a magnitude comparable 299 
to that in DEE (ORPTV = 1.4, adjPPTV = 9.1×10-5; ORMPC = 1.2, adjPMPC = 5.5×10-3), but was not 300 
significant in individuals with NAFE (ORPTV = 1.2, adjPPTV = 0.062; ORMPC =1.0, adjPMPC = 0.37; 301 
Figure 1). There was no evidence of excess burden in synonymous URVs, suggesting that 302 
enrichment of deleterious pathogenic variants was unlikely to be the result of un-modeled 303 
population stratification or technical artifact. Among in-silico missense predictors, MPC≥2 304 
annotations consistently showed a higher burden than those predicted by PolyPhen-2 and SIFT. 305 
The burden among missense-constrained genes exhibited a similar pattern, with PTVs showing 306 
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a higher burden in DEE than in the common epilepsy types (Figure S14). In addition, both large 307 
gene sets were more enriched for PTVs than for damaging missense variants. 308 
 309 
Burden in candidate genetic etiologies associated with epilepsy 310 
Among URVs in previously reported epilepsy genes, we found an expected and pronounced 311 
difference in the number of singleton protein-truncating URVs in individuals with DEE relative to 312 
controls. PTVs were associated with an increased DEE risk in 43 known dominant epilepsy 313 
genes17 (OR = 6.3, adjP = 2.1×10-08), 50 known dominant DEE genes9 (OR = 9.1, adjP = 7.8×10-314 
11), and 33 genes with de novo burden in neurodevelopmental disorders with epilepsy9 (OR = 315 
14.8, adjP =1.7×10-12). Evidence for an excess of ultra-rare PTVs was also observed in individuals 316 
with GGE, with an odds ratio ranging from 2 to 4. No enrichment of PTVs was observed among 317 
people with NAFE (Figure 2A; Table S8). In contrast, the burden of singleton missense (MPC≥2) 318 
URVs was more pervasive across epilepsy types. Compared to controls, there was a 3.6-fold 319 
higher rate of these missense URVs in established epilepsy genes in individuals with DEE (adjP 320 
= 1.6×10-10), a 2.3-fold elevation in individuals with GGE (adjP = 6.4×10-07), and a 1.9-fold 321 
elevation in individuals with NAFE (adjP = 2.8×10-4).  322 
 323 
Burden in genes encoding for cation channels and neurotransmitter receptors 324 
Among brain-enriched genes—those defined as genes with at least a 2-fold increase in 325 
expression in brain tissues relative to their average expression across tissues based on GTEx 326 
data32—both protein-truncating and damaging missense (MPC≥2) URVs were significantly 327 
enriched in epilepsy cases versus controls, and the missense burden was much higher than the 328 
PTV burden (Figure S15). We then investigated the burden in four smaller gene sets previously 329 
implicated as mechanisms driving the etiology of epilepsy; these included 19 genes encoding 330 
GABAA receptor subunits, 113 genes involved in GABAergic pathways, 34 genes encoding 331 
excitatory receptors (ionotropic glutamate receptor subunits and nicotinic acetylcholine receptor 332 
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subunits), and 86 voltage-gated cation channel genes (e.g., sodium, potassium, calcium—full  list 333 
in Table S6)18. We discovered that, relative to damaging missense variants, the distribution of 334 
PTVs in most of these gene sets did not differ significantly between epilepsy cases and controls 335 
(Figure 2A; Table 1). The PTV signals that remained significant after FDR correction included, 336 
for individuals with DEE, an increased burden in GABAergic pathway genes and voltage-gated 337 
cation channels, and noticeably, for individuals with GGE, an increased burden in the inhibitory 338 
GABAA receptors (OR = 4.8, adjP = 0.021). No PTV burden was detected for individuals with 339 
NAFE. In contrast, the enrichment of missense (MPC≥2) URVs was more extensive in these gene 340 
sets across all epilepsy-control comparisons (Figure 2A; Table 1). The burden of these damaging 341 
missense pathogenic variants was seen in GABAA receptor genes (ORDEE = 3.7, adjPDEE = 0.028; 342 
ORGGE = 3.8, adjPGGE = 1.4×10-3; ORNAFE = 2.7, adjPNAFE = 0.039), GABAergic pathway genes 343 
(ORDEE = 2.6, adjPDEE = 4.7×10-5; ORGGE = 1.9, adjPGGE = 9.9×10-04; ORNAFE = 1.4, adjPNAFE = 344 
0.11), and voltage-gated cation channel genes (ORDEE = 2.1, adjPDEE = 1.7×10-03; ORGGE = 1.5, 345 
adjPGGE = 0.023; ORNAFE = 1.4, adjPNAFE = 0.081). However, no enrichment was detected in genes 346 
encoding excitatory receptors. For individuals with NAFE, the burden signals were consistently 347 
the weakest across gene sets compared to the other epilepsy phenotypes. None of the gene sets 348 
was enriched for putatively neutral variation, except for a slightly elevated synonymous burden in 349 
GABAA receptor genes (Table S8). These results support a recent finding where rare missense 350 
variation in GABAA receptor genes conferred a significant risk to GGE18, and together implicate 351 
the relative importance and involvement of damaging missense variants in abnormal inhibitory 352 
neurotransmission in both rare and common epilepsy types. 353 
For gene sets other than the three lists of previously associated genes (Table S6; 74 non-354 
overlapping genes in total), we evaluated the residual burden of URVs after correcting for events 355 
in the 74 known genes. For the gene sets of cation channel and neurotransmitter receptor genes, 356 
the adjusted burden signals of singleton deleterious URVs was largely reduced, with some weak 357 
associations remaining in GABAA receptor-encoding or GABAergic genes among individuals with 358 
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DEE or GGE. For the larger gene groups of constrained genes and brain-enriched genes, burden 359 
signals were attenuated but many remained significant, especially the strong enrichment of 360 
missense MPC≥2 variants in brain-enriched genes across all three classes of epilepsy (Figure 361 
S16). These findings suggest that although most gene burden is driven by previously identified 362 
genes, more associations could be uncovered with larger sample sizes. 363 
 364 
Gene-based collapsing analysis recapture known genes for DEE 365 
For gene discovery, because both protein-truncating and damaging missense (MPC≥2) URVs 366 
showed an elevated burden in epilepsy cases, we aggregated both together as deleterious 367 
pathogenic variants along with in-frame insertions and deletions in our gene collapsing analysis. 368 
This amassed to a total of 46,917 singleton URVs and 52,416 URVs with AC≤3.  Surprisingly, 369 
for individuals diagnosed with DEE, we re-identified several of the established candidate DEE 370 
genes as top associations (Figure 3A). Although screening was not performed systematically, 371 
many DEE patients were screened-negative for these genes using clinical gene panels prior to 372 
enrollment. Based on the results of singleton URVs, SCN1A was the only gene that reached 373 
exome-wide significance (OR = 18.4, P = 5.8×10-8); other top-ranking known genes included 374 
NEXMIF (previously known as KIAA2022; OR > 99, P = 1.6×10-6), KCNB1 (OR = 20.8, P = 375 
2.5×10-4), SCN8A (OR = 13.8, P = 6.1×10-4), and SLC6A1 (OR = 11.1, P = 3.6×10-3) (Table S10). 376 
Some carriers of deleterious URVs in lead genes were affected individuals with a normal result 377 
for gene panel testing; for example, 2 out of the 3 carriers of qualified URVs for PURA and 2 out 378 
of 5 for KCNB1 had undergone previous genetic screening. (Table S7). This could be because 379 
different sample-contributing sites adopted different gene panels and not all of them included the 380 
lead genes found to carry variants qualifying from this study, or that during screening patients 381 
were found to carry a variant of uncertain significance that did not satisfy the ACMG guidelines39. 382 
The gene burden results held up when considering URVs with AC≤3, often showing even stronger 383 
associations; two other well-studied genes, STXBP1 (OR = 13.3, P = 1.4×10-5) and WDR45 (OR 384 
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> 49, P = 1.2×10-3), emerged on top, both of which have been implicated in DEE and 385 
developmental disorders (Table S11). 386 
 387 
Channel and transporter genes implicated in common epilepsies 388 
When evaluating gene burden in the GGE and NAFE epilepsy subgroups, we did not identify any 389 
exome-wide significant genes. However, several candidate epilepsy genes made up the lead 390 
associations, including ion channel and transporter genes known to cause rare forms of epilepsy. 391 
For the GGE case-control analysis in singleton deleterious URVs, the lead associations included 392 
four previously-associated genes (EEF1A2, OR = 32, P = 3.8×10-4; GABRG2, OR = 19.0, P = 393 
6.2×10-4; SLC6A1, OR = 7.3, P = 2.0×10-3; and GABRA1, OR = 9.5, P = 2.2×10-3), and two genes 394 
(CACNA1G, OR = 9.1, P = 2.5×10-4; UNC79, OR = 19.0, P = 6.2×10-4) that were not previously 395 
linked to epilepsy but are both highly expressed in the brain and under evolutionary constraint 396 
(Figures 3B; Table S12). Although evidence has been mixed, CACNA1G was previously 397 
implicated as a potential susceptibility gene for GGE in mutational analysis40 and reported to 398 
modify mutated sodium channel (SCN2A) activity in epilepsy41. UNC79 is an essential part of the 399 
UNC79-UNC80-NALCN channel complex that influences neuronal excitability by interacting with 400 
extracellular calcium ions42, and this channel complex has been previously associated with 401 
infantile encephalopathy43. Notably, all these lead genes were more enriched for damaging 402 
missense (MPC≥2) than for protein-truncating URVs despite the lower rate of MPC≥2 variants 403 
relative to PTVs (Table S12).  404 
For individuals with NAFE, the analysis of singleton deleterious URVs identified LGI1 and 405 
TRIM3 as the top two genes carrying a disproportionate number of deleterious URVs, however 406 
neither reached exome-wide significance (OR > 32, P = 2.1×10-4). GABRG2, a lead association 407 
in individuals with GGE, was among the top ten most enriched genes, along with two brain-408 
enriched, constrained genes (PPFIA3, OR = 8.2, P = 4.2×10-3; and KCNJ3, OR = 16.4, P = 409 
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1.2×10-3). GABRG2 has previously been reported to show an enrichment of variants compared 410 
to controls in a cohort of individuals with Rolandic epilepsy (childhood epilepsy with 411 
centrotemporal spikes) or related phenotypes, the most common group of focal epilepsies of 412 
childhood44. Two other genes previously associated with epilepsy, DEPDC5 and SCN8A (both 413 
OR = 5.5, P = 0.01), were among the top twenty associations (Figures 3C; Table S14). LGI1 and 414 
DEPDC5 are established genes for focal epilepsy, and DEPDC5 was the only exome-wide 415 
significant hit in the Epi4K WES study for familial NAFE cases17. TRIM3 has not been previously 416 
implicated in epilepsy, but evidence from a mouse model study implicates it in regulation of 417 
GABAA receptor signaling and thus modulation of seizure susceptibility45. Single gene burden for 418 
both GGE and NAFE remained similar when considering URVs with an allele count up to AC≤3 419 
(Tables S13 & S15). Gene burden tests collapsing all epilepsy phenotypes recapitulated the lead 420 
genes in each of the subgroup-specific analyses, but none of the genes achieved exome-wide 421 
significance (Tables S16 & S17). It is worth noting that some of the genes were enriched for 422 
deleterious URVs among the “controls”, which is clearly driven by non-neuropsychiatric disease 423 
ascertainment for many of the available controls (e.g., LDLR in Table S16; most control carriers 424 
were individuals with cardiovascular diseases from the MIGen cohorts in Table S2). Thus, these 425 
should not be interpreted as potential protective signals for epilepsy. 426 
 427 
Recessive model, SKAT gene test, and single variant association 428 
The secondary gene-based test of a recessive model did not identify genes that differed 429 
significantly in the carrier rate of homozygous deleterious variants between epilepsy-affected 430 
individuals and controls (Table S18). Even if we considered variants up to MAF < 0.01, for most 431 
of the lead genes, only one case carrier was identified. For the DEE cohort, these genes included 432 
recessive genes previously implicated, such as ARV1, BRAT1, CHRDL46 with a homozygous PTV 433 
and OPHN146 with a recessive missense (MPC≥2) variant (Table S18A). For the two common 434 
forms of epilepsy, a few studied recessive epilepsy genes were also observed in the lead gene 435 
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associations, such as SLC6A846 (a homozygous PTV) for GGE (Table S18B), and SLC6A8 (a 436 
homozygous missense-MPC) and SYN146 (a homozygous PTV) for NAFE (Table S18C). One 437 
GGE-affected individual was found homozygous for an in-frame deletion on CHD2, a dominant 438 
DEE gene46 (Table S18B). These findings suggest an even larger cohort will be needed to identify 439 
with clarity risk genes that act in a recessive manner for different groups of epilepsy. 440 
Beyond URVs, we studied the contribution of low frequency deleterious variants to 441 
epilepsy risk using SKAT (MAF < 0.01). Top associations for individuals with DEE included known 442 
genes, such as missense-enriched STXBP1 (P = 9.3×10-9), KCNA2 (P = 1.0×10-5; Figure S17), 443 
and PTV-enriched NEXMIF (P = 7.1×10-8), and SCN1A (P = 3.9×10-4; Figure S18). However, no 444 
significant gene enrichment was observed for the two common types of epilepsy or when 445 
combining all epilepsy cases. The tests for PTVs and missense variants with MPC≥2 were mostly 446 
underpowered due to sparse observations (Figure S17 & S18).  No individual low-frequency 447 
variant (MAF > 0.001) was significantly associated with overall epilepsy or with any of the studied 448 
epilepsy phenotypes (Figure S19). The primary gene-based test results and single variant 449 
associations are available on our Epi25 WES browser (Web Resources).  450 
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Discussion 451 
In the largest exome study of epilepsies to date, we show that ultra-rare deleterious coding 452 
variation—variation absent in a large population-based exome database—is enriched in both rare 453 
and common epilepsy syndromes when compared to ancestrally matched controls. When all 454 
genes were considered in the tested gene sets, PTVs showed a more significant signal than 455 
missense variants with an MPC≥2, and enrichment in deleterious URVs was more pronounced in 456 
individuals diagnosed with DEE and GGE relative to NAFE. While no single gene surpassed 457 
exome-wide significance in the non-hypothesis-driven analysis for GGE or NAFE, specific gene 458 
groups previously associated with epilepsy or encoding biologically interesting entities showed a 459 
clear enrichment of deleterious URVs. Specifically, we observed a significant excess of 460 
deleterious URVs in constrained genes, established epilepsy genes, GABAA receptor subunit 461 
genes, a larger group of genes delineating the GABAergic pathway, and all cation channel-462 
encoding genes. Our results thus support the concept that defects in GABAergic inhibition 463 
underlie various forms of epilepsy. These findings, based on a more than 5-fold increase in 464 
sample size over previous exome-sequencing studies17-19; 47, clearly reveal observations that have 465 
been hypothesized for common epilepsies from studies of rare, large monogenic families, and 466 
confirm that the same genes are relevant in both settings. Thus, a further increase in sample size 467 
will continue to unravel the complex genetic architecture of common epilepsies. Interestingly, no 468 
enrichment was seen in genes encoding the excitatory glutamate and acetylcholine receptors. 469 
For GGE, this difference between variants in inhibitory versus excitatory receptor genes may be 470 
real, as excitatory receptor variants have not been shown so far in single subjects or families. In 471 
NAFE, however, we suspect that it is probably due to a lack of power and/or genetic heterogeneity, 472 
since genetic variants in specific subunits of nicotinic acetylcholine and NMDA receptors have 473 
been described extensively in different types of non-acquired familial focal epilepsies48.  474 
Notably, our overall finding of a mild to moderate burden of deleterious coding URVs in 475 
NAFE (Figure 1 & 2) contrasts with results reported in the Epi4K WES study, where the familial 476 
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NAFE cohort showed a strong enrichment signal of ultra-rare functional variation in known 477 
epilepsy genes and ion channel genes17. In addition, our findings for GGE showed a genetic risk 478 
comparable or even stronger than the Epi4K familial GGE cohort. The strong signal in our GGE 479 
cohort likely reflects the larger sample size, whereas the weaker signal in our NAFE cohort is 480 
most likely due to differences in patient ascertainment. In Epi4K the cohort was deliberately 481 
enriched with familial cases, most of whom had an affected first-degree relative and were 482 
ascertained in sibling or parent-child pairs or multiplex families, and familial NAFE is relatively 483 
uncommon. In the Epi25 collaboration, a positive family history of epilepsy was not a requirement 484 
and only 9% of DEE, 12% of GGE, and 5% of NAFE patients had a known affected first-degree 485 
relative. Indeed, our results were consistent with the Epi4K sporadic NAFE cohort, where no 486 
signals of enrichment were observed17; 49. This difference may reflect the substantial etiological 487 
and genetic heterogeneity of epilepsy even within subgroups especially in NAFE. In particular, 488 
the dramatically weaker genetic signals, per sample, observed in individuals with NAFE studied 489 
here compared with those in the previous Epi4K study illustrate a pronounced difference in the 490 
genetic signals associated with familial and non-familial NAFE. The reasons for this striking 491 
difference remain to be elucidated. Comparing the two common classes of epilepsy, our findings 492 
showed a larger genetic burden from URVs for GGE relative to NAFE, which could be due to 493 
heterogeneity in electroclinical syndromes within each class and should not be viewed as 494 
conclusive. On the other hand, in the latest GWAS of common epilepsies of 15,212 cases and 495 
29,677 controls from the ILAE Consortium15, fewer GWAS hits were discovered and less 496 
heritability was explained by common genetic variation for the focal epilepsy cohort (9.2%) 497 
compared to the GGE cohort (32.1%), suggesting that current evidence from both common and 498 
rare variant studies are converging on a larger genetic component underlying the etiology of non-499 
familial cases of GGE relative to NAFE, as originally postulated. 500 
We found that ultra-rare missense variants with an MPC score28 ≥ 2 (2.0% of missense 501 
variants) were enriched in individuals with epilepsy at an effect size approaching PTVs in the 502 
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investigated gene groups. For common epilepsy types, the burden of these missense variants 503 
(MPC≥2) was even more prominent than PTVs in known epilepsy genes and GABAergic genes 504 
(Figure 2). At the gene level, some of the top channel genes (e.g. GABRG2, CACNA1G) carried 505 
a higher number of missense variants (MPC≥2) than PTVs in people with epilepsy. For instance, 506 
in the gene-based collapsing analysis considering all epilepsies, 15 GABRG2 pathogenic variants 507 
were found in epilepsy-affected individuals (including 7 GGE and 7 NAFE; Tables S12, 14 & 16) 508 
versus only 1 pathogenic variant in controls; among the case-specific pathogenic variants, one 509 
was a splice site mutation, while the other 14 were all missense variants (MPC≥2) (Figure S20), 510 
linking to an impaired channel function. This is in line with findings from a recent exome-wide 511 
study of 6,753 individuals with neurodevelopmental disorder with and without epilepsy9 that 512 
detected an association of missense de novo variants with the presence of epilepsy, particularly 513 
when considering only ion channel genes. A disease-association of missense variants rather than 514 
PTVs points to a pathophysiological mechanism of protein-alteration (e.g., gain-of-function or 515 
dominant-negative effects) rather than haploinsufficiency, but ultimately only functional tests can 516 
elucidate these mechanisms. A recent study on the molecular basis of 6 de novo missense 517 
variants in GABRG2 identified in DEE reported an overall reduced inhibitory function of GABRG2 518 
due to decreased cell surface expression or GABA-evoked current amplitudes, suggesting 519 
GABAergic disinhibition as the underlying mechanism50. Surprisingly, 2 of those recurrent de novo 520 
missense variants were seen in two GGE-affected individuals in our study (A106T and R323Q), 521 
and another recently reported variant in GABRB2 (V316I) also occurred both de novo in DEE51 522 
and as an inherited variant in a GGE family showing a loss of receptor function18. This suggests 523 
that changes in protein function from the same missense pathogenic variant may cause not only 524 
severe epilepsy syndromes, but also contribute to common epilepsies with milder presentations, 525 
similar to what is known about variable expressivity in large families carrying GABRG2 variants48; 526 
52-54. Reduced receptor function due to GABRG2 variants has been also shown for childhood 527 
epilepsy with centrotemporal spikes previously44; 54, which belong to the NAFE group in this study. 528 
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Moving forward, discovering how variant-specific perturbations of the neurotransmission and 529 
signaling system in a gene can link to a spectrum of epilepsy syndromes will require in-depth 530 
functional investigation. 531 
Although we have increased the sample size from the Epi4K and EuroEPINOMICS WES 532 
studies for both GGE and NAFE subgroups by more than 5-fold, the phenotypic and genetic 533 
heterogeneity of common epilepsies—on par with other complex neurological and 534 
neuropsychiatric conditions—will require many more samples to achieve statistical power for 535 
identifying exome-wide significant genes. Furthermore, while we implemented stringent QC to 536 
effectively control for the exome capture differences between cases and controls, this 537 
concomitantly resulted in a loss of a substantial amount of the called sites and reduced our 538 
detection power to identify associated variants. As sample sizes grow, the technical variation 539 
across projects and sample collections will remain a challenge in large-scale sequencing studies 540 
relying on a global collaborative effort. 541 
With this largest epilepsy WES study to date, we demonstrated a strong replicability of 542 
existing gene findings in an independent cohort. GABAA receptor genes affected by predicted- 543 
pathogenic missense variants were enriched across the three subgroups of epilepsy. An ongoing 544 
debate in epilepsy genetics is the degree to which generalized and focal epilepsies segregate 545 
separately, and whether their genetic determinants are largely distinct or sometimes shared4; 55. 546 
Whilst clinical evidence for general separation of pathophysiological mechanisms in these two 547 
forms is strong, and most monogenic epilepsy families segregate either generalized or focal 548 
syndromes, the distinction is not absolute. Here, the finding of rare variants in GABAA receptor 549 
genes in both forms adds weight to the case for shared genetic determinants. 550 
Our results suggest that clinical presentations of common epilepsy types with complex 551 
inheritance patterns have a combination of both common and rare genetic risk variants. The latest 552 
ILAE epilepsy GWAS of over 15,000 patients and 25,000 controls identified 16 genome-wide 553 
significant loci for common epilepsies15, mapped these loci to ion channel genes, transcriptional 554 
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factors, and pyridoxine metabolism, and implicated a role in epigenetic regulation of gene 555 
expression in the brain. A combination of rare and common genetic association studies with large 556 
sample sizes, along with the growing evidence from studies of copy number variation and tandem 557 
repeat expansions in epilepsy12; 56; 57, will further decipher the genetic landscape of common 558 
epilepsy subgroups. The ongoing effort of the Epi25 collaborative is expected to double the patient 559 
cohorts in upcoming years with the goal of elucidating shared and distinct gene discoveries for 560 
common and rare forms of epilepsy, ultimately facilitating precision medicine strategies in the 561 
treatment of epilepsy.  562 
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Supplemental Data 563 
Supplemental data includes affiliations of the contributing authors, descriptions of patient 564 
recruitment and phenotyping from individual participating cohorts, supplemental acknowledgment, 565 
20 figures and 18 tables. 566 
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Figure titles and legends 829 
Figure 1. Burden of ultra-rare singletons in LoF-intolerant genes (pLI > 0.995) 830 
This analysis was restricted to 4,042 non-ExAC controls for comparison with epilepsy cases. We 831 
focused on “ultra-rare” variants not observed in the DiscovEHR database. Significance of 832 
association was displayed in FDR-adjusted p-values; odds ratios and 95% CIs were not 833 
multiplicity adjusted. The five functional coding annotations were defined as described in Table 834 
S5. PTV denotes protein-truncating variants; the “damaging missense” and “benign missense” 835 
categories were predicted by PolyPhen-2 and SIFT, while “damaging missense-MPC” was a 836 
group of missense variants with a missense badness score (MPC) ≥ 2. From top to bottom are 837 
the results based on all-epilepsy, DEE, GGE, and NAFE. Epilepsy cases, except for individuals 838 
with NAFE, carried a significant excess of ultra-rare PTV and damaging missense (MPC≥2) 839 
variants compared to controls (FDR < 0.05). PTV burden was higher than missense (MPC≥2) 840 
burden across epilepsy types. 841 
 842 
Figure 2. Burden of ultra-rare singletons annotated as (A) protein-truncating variants or (B) 843 
damaging missense (MPC≥2) variants 844 
“Ultra-rare” variants (URVs) were defined as not observed in the DiscovEHR database. Gene sets 845 
were defined in Table S6, with the number of genes specified in the parenthesis. DEE stands for 846 
individuals with developmental and epileptic encephalopathies, GGE for genetic generalized 847 
epilepsy, NAFE for non-acquired focal epilepsy, and EPI for all epilepsy; NDD-EPI genes are 848 
genes with de novo burden in neurodevelopmental disorders with epilepsy. Star signs indicate 849 
significance after FDR control (“*”: FDR-adjusted p-value < 0.05; “**”: adjusted p-value < 1×10-3; 850 
“***”: adjusted p-value < 1×10-5). PTVs were enriched in candidate epilepsy genes for individuals 851 
with DEE relative to other epilepsy subgroups, but did not show a strong signal in inhibitory, 852 
excitatory receptors or voltage-gated cation channel genes. The burden of damaging missense 853 
(MPC≥2) variants, on the other hand, was stronger across these gene sets compared to PTVs, 854 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/525683doi: bioRxiv preprint first posted online Jan. 21, 2019; 
35 
especially for GABAA receptor genes and genes involved in GABAergic pathways. Relative to 855 
other epilepsy types, individuals with NAFE consistently showed the least burden of deleterious 856 
URVs. No enrichment was observed from excitatory receptors. 857 
 858 
Figure 3. Gene burden for individuals diagnosed with (A) developmental and epileptic 859 
encephalopathies, (B) genetic generalized epilepsy, or (C) non-acquired focal epilepsy  860 
This analysis focused on ultra-rare (non-DiscovEHR) singleton variants annotated as PTV, 861 
damaging missense (MPC≥2), or in-frame insertion/deletion and used Fisher’s exact test to 862 
identify genes with a differential carrier rate of these ultra-rare deleterious variants in individuals 863 
with epilepsy compared to controls. Exome-wide significance was defined as p-value < 6.8e-07 864 
after Bonferroni correction (Methods). Only SCN1A achieved exome-wide significance for 865 
individuals with DEE.866 
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Table 1. Enrichment of ultra-rare protein-truncating or damaging missense (MPC≥2) singletons in epilepsy 
This analysis compared the burden of deleterious pathogenic variants between cases and controls using logistic 
regression, adjusting for sex, the first ten principal components, and overall variant count. FDR correction was based on a 
full list of burden tests in Table S8. Tested epilepsy types included all epilepsies (EPI; N=9,170), developmental and 
epileptic encephalopathies (DEE; N=1,021), genetic generalized epilepsy (GGE; N=3,108), and non-acquired focal 
epilepsy (NAFE; N=3,597). All were compared against 8,436 control samples. Figure 2 shows the enrichment pattern of 
PTVs and MPC≥2 variants across the seven gene sets listed here. 
Gene set  
(# genes) 
Mutation 
(# variants) 
Epilepsy 
type 
Carriers (N) 
OR 95%CI P-value FDR adj. P cases controls 
Known 
epilepsy 
genes 
(43) 
PTV 
(95) 
EPI 67 27 2.37 (1.50-3.74) 2.0e-04 1.2e-03 
DEE 24 27 6.28 (3.48-11.3) 1.0e-09 2.1e-08 
GGE 22 27 2.33 (1.32-4.11) 3.6e-03 1.4e-02 
NAFE 15 27 1.38 (0.72-2.66) 3.4e-01 4.7e-01 
MPC≥2 
(335) 
EPI 235 98 2.21 (1.74-2.81) 1.1e-10 2.8e-09 
DEE 47 98 3.60 (2.50-5.19) 5.0e-12 1.6e-10 
GGE 85 98 2.31 (1.71-3.12) 4.4e-08 6.4e-07 
NAFE 80 98 1.91 (1.41-2.60) 3.3e-05 2.8e-04 
Known DEE 
genes 
(50) 
PTV 
(89) 
EPI 68 21 3.00 (1.82-4.95) 1.8e-05 1.6e-04 
DEE 27 21 9.13 (4.93-16.9) 2.1e-12 7.8e-11 
GGE 25 21 3.57 (1.95-6.54) 3.7e-05 3.0e-04 
NAFE 10 21 1.05 (0.48-2.29) 9.1e-01 9.3e-01 
MPC≥2 
(327) 
EPI 224 101 2.05 (1.61-2.60) 6.5e-09 1.2e-07 
DEE 54 101 4.20 (2.97-5.95) 6.0e-16 1.3e-13 
GGE 85 101 2.22 (1.64-3.00) 2.0e-07 2.6e-06 
NAFE 63 101 1.42 (1.02-1.97) 3.7e-02 8.8e-02 
Neuro-
developmental 
disorders with 
epilepsy 
(33) 
PTV 
(63) 
EPI 49 14 3.22 (1.75-5.90) 1.6e-04 9.9e-04 
DEE 29 14 14.77 (7.4-29.49) 2.3e-14 1.7e-12 
GGE 14 14 2.86 (1.32-6.17) 7.7e-03 2.7e-02 
NAFE 4 14 0.75 (0.24-2.34) 6.2e-01 7.2e-01 
MPC≥2 
(215) 
EPI 149 65 2.11 (1.57-2.84) 9.4e-07 1.1e-05 
DEE 36 65 4.30 (2.81-6.57) 1.8e-11 5.1e-10 
GGE 54 65 2.18 (1.50-3.17) 4.2e-05 3.2e-04 
NAFE 41 65 1.43 (0.96-2.15) 8.0e-02 1.6e-01 
GABA-A 
receptors 
(19) 
PTV 
(17) 
EPI 12 5 1.99 (0.69-5.74) 2.0e-01 3.2e-01 
DEE 1 5 2.25 (0.25-20.2) 4.7e-01 6.0e-01 
GGE 9 5 4.81 (1.57-14.7) 5.9e-03 2.1e-02 
NAFE 1 5 0.37 (0.04-3.27) 3.7e-01 5.0e-01 
MPC≥2 
(62) 
EPI 49 13 3.25 (1.74-6.07) 2.1e-04 1.2e-03 
DEE 7 13 3.65 (1.39-9.54) 8.3e-03 2.8e-02 
GGE 21 13 3.81 (1.86-7.81) 2.5e-04 1.4e-03 
NAFE 15 13 2.67 (1.23-5.77) 1.3e-02 3.9e-02 
GABAergic 
pathway 
(113) 
PTV 
(127) 
EPI 81 44 1.58 (1.10-2.28) 1.4e-02 4.4e-02 
DEE 16 44 2.46 (1.37-4.39) 2.4e-03 1.0e-02 
GGE 28 44 1.60 (0.99-2.57) 5.3e-02 1.1e-01 
NAFE 24 44 1.19 (0.73-1.95) 4.9e-01 6.1e-01 
MPC≥2 
(287) 
EPI 185 101 1.73 (1.35-2.22) 1.6e-05 1.6e-04 
DEE 34 101 2.62 (1.74-3.95) 4.5e-06 4.7e-05 
GGE 68 101 1.86 (1.35-2.56) 1.6e-04 9.9e-04 
NAFE 58 101 1.40 (1.00-1.95) 4.7e-02 1.1e-01 
Excitatory 
receptors 
(34) 
PTV 
(54) 
EPI 22 32 0.66 (0.37-1.15) 1.4e-01 2.5e-01 
DEE 3 32 0.71 (0.21-2.35) 5.7e-01 6.7e-01 
GGE 11 32 1.10 (0.54-2.23) 8.0e-01 8.4e-01 
NAFE 5 32 0.44 (0.17-1.15) 9.5e-02 1.8e-01 
MPC≥2 
(80) 
EPI 47 33 1.28 (0.81-2.02) 2.9e-01 4.3e-01 
DEE 9 33 1.76 (0.81-3.81) 1.5e-01 2.6e-01 
GGE 12 33 0.91 (0.46-1.79) 7.8e-01 8.3e-01 
NAFE 20 33 1.50 (0.84-2.65) 1.7e-01 2.8e-01 
Voltage-gated 
cation 
channels 
(86) 
PTV 
(163) 
EPI 100 63 1.45 (1.05-2.01) 2.5e-02 7.0e-02 
DEE 18 63 2.11 (1.21-3.66) 8.2e-03 2.8e-02 
GGE 31 63 1.38 (0.88-2.16) 1.6e-01 2.7e-01 
NAFE 30 63 1.15 (0.73-1.81) 5.5e-01 6.7e-01 
MPC≥2 
(329) 
EPI 206 121 1.51 (1.20-1.90) 4.7e-04 2.4e-03 
DEE 34 121 2.08 (1.40-3.10) 3.1e-04 1.7e-03 
GGE 73 121 1.52 (1.12-2.07) 6.6e-03 2.3e-02 
NAFE 74 121 1.39 (1.03-1.88) 3.1e-02 8.1e-02 
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